In a boost to the companies' come-from-behind immunotherapy bid, their drug Libtayo helped patients live longer than did chemotherapy. Improving on Keytruda, however, will be more challenging.

$SNY $REGN $MRK $BMY

https://t.co/CYnMAR5qnq